Grapefruit–drug interactions

grapefruit interacts with the effects of some drugs

Grapefruit–drug interactions refer to the phenomenon where consumption of grapefruit or grapefruit juice affects the metabolism of certain medications, leading to either diminished or enhanced drug effects. This interaction is a significant concern in pharmacology and clinical medicine due to its potential to alter therapeutic outcomes or cause adverse effects. The grapefruit, a common citrus fruit, is known for its unique taste and nutritional value, but it is also notable for its potential to interfere with the metabolism of numerous drugs. As of 2014, over 85 medications have been identified that may interact adversely with grapefruit. These interactions can lead to either subtherapeutic drug levels or dangerously high concentrations of active substances in the bloodstream.

Mechanism of Interaction

The interaction is primarily due to organic compounds in grapefruit known as furanocoumarins. These compounds inhibit the activity of cytochrome P450 3A4 (CYP3A4), an enzyme present in both the liver and the small intestine that plays a central role in the first-pass metabolism of many orally administered drugs.

When CYP3A4 is inhibited, drugs that are normally broken down by this enzyme may remain in the body at higher concentrations for longer periods, increasing the risk of side effects or toxicity. In contrast, some drugs may become less effective if their activation requires metabolic conversion by CYP3A4.

Commonly Affected Drugs

Grapefruit interactions can affect a wide variety of medications, including but not limited to:

• Statins (e.g., simvastatin, atorvastatin) – increased risk of rhabdomyolysis
• Calcium channel blockers (e.g., felodipine, nifedipine) – excessive hypotension
• Immunosuppressants (e.g., cyclosporine, tacrolimus) – increased nephrotoxicity
• Benzodiazepines (e.g., midazolam, triazolam) – enhanced sedative effects
• Antihistamines (e.g., fexofenadine) – altered absorption
• Psychotropic drugs (e.g., quetiapine, buspirone) – increased central nervous system effects

Clinical Implications

Healthcare providers should be vigilant when prescribing medications that are metabolized by CYP3A4 and advise patients to avoid grapefruit products if a potential interaction exists. Even a single serving of grapefruit juice can inhibit intestinal CYP3A4 for over 24 hours, meaning spacing the intake of grapefruit and the drug will not necessarily prevent the interaction.

Alternatives and Precautions

Patients who enjoy citrus fruits can often substitute oranges, lemons, or limes, which do not contain the same inhibitory compounds. However, Seville oranges (used in marmalade), pomelos, and tangelos may have similar effects as grapefruit and should also be avoided with susceptible medications.

See Also

• Drug metabolism
• Cytochrome P450
• Enzyme inhibition
• First-pass effect
• Pharmacokinetics